TKNO Q3 2022 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$135M

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$11M+13.8% YoY

Gross Profit

$5M44.6% margin

Operating Income

-$23M-214.7% margin

Net Income

-$22M-210.2% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

-8.5%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$15M

Stock-Based Comp.

$968,000

Balance Sheet

Total Assets

$160M

Total Liabilities

$48M

Stockholders' Equity

$112M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$9M	+13.8%
Gross Profit	$5M	$4M	+11.9%
Operating Income	-$23M	-$4M	-490.4%
Net Income	-$22M	-$3M	-591.3%

Revenue Segments

Lab Essentials

$9M89%

Clinical Solutions

$919,0009%

Other Product

$303,0003%

Geographic Segments

UNITED STATES

$10M97%

Non-US

$308,0003%